{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:07:48Z","timestamp":1784891268925,"version":"3.55.0"},"reference-count":190,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T00:00:00Z","timestamp":1416182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Nowadays, Cannabis sativa is considered the most extensively used narcotic. Nevertheless, this fame obscures its traditional employ in native medicine of South Africa, South America, Turkey, Egypt and in many regions of Asia as a therapeutic drug. In fact, the use of compounds containing Cannabis and their introduction in clinical practice is still controversial and strongly limited by unavoidable psychotropic effects. So, overcoming these adverse effects represents the main open question on the utilization of cannabinoids as new drugs for treatment of several pathologies. To date, therapeutic use of cannabinoid extracts is prescribed in patients with glaucoma, in the control of chemotherapy-related vomiting and nausea, for appetite stimulation in patients with anorexia-cachexia syndrome by HIV, and for the treatment of multiple sclerosis symptoms. Recently, researcher efforts are aimed to employ the therapeutic potentials of Cannabis sativa in the modulation of cannabinoid receptor activity within the central nervous system, particularly for the treatment of neurodegenerative diseases, as well as psychiatric and non-psychiatric disorders. This review evaluates the most recent available data on cannabinoids utilization in experimental and clinical studies, and highlights their beneficial effects in the prevention of the main neurological diseases and for the clinical treatment of symptoms with them correlated.<\/jats:p>","DOI":"10.3390\/molecules191118781","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T10:19:13Z","timestamp":1416219553000},"page":"18781-18816","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Cannabinoids: New Promising Agents in the Treatment of Neurological Diseases"],"prefix":"10.3390","volume":"19","author":[{"given":"Sabrina","family":"Giacoppo","sequence":"first","affiliation":[{"name":"IRCCS Centro Neurolesi \"Bonino-Pulejo\", Via Provinciale Palermo, contrada Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mandolino","sequence":"additional","affiliation":[{"name":"Consiglio per la Ricerca e la sperimentazione in Agricoltura, Centro di Ricerca per le Colture Industriali (CRA-CIN), Via di Corticella 133, 40128 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Galuppo","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \"Bonino-Pulejo\", Via Provinciale Palermo, contrada Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Placido","family":"Bramanti","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \"Bonino-Pulejo\", Via Provinciale Palermo, contrada Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5073-717X","authenticated-orcid":false,"given":"Emanuela","family":"Mazzon","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \"Bonino-Pulejo\", Via Provinciale Palermo, contrada Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2014,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1508\/cytologia.63.459","article-title":"Characterization, genome sizes and morphology of sex chromosomes in hemp (Cannabis sativa L.)","volume":"63","author":"Sakamoto","year":"1998","journal-title":"Cytologia"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ranalli, P. (2007). Improvement of Crop Plants for Industrial End Uses, Springer.","DOI":"10.1007\/978-1-4020-5486-0"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.2135\/cropsci2001.1682","article-title":"Comparison of Hemp Varieties Using Random Amplified Polymorphic DNA Markers","volume":"41","author":"Forapani","year":"2001","journal-title":"Crop. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1096\/fj.00-0399fje","article-title":"Endocannabinoids control spasticity in a multiple sclerosis model","volume":"15","author":"Baker","year":"2001","journal-title":"FASEB J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1093\/jxb\/ern260","article-title":"Phytochemical and genetic analyses of ancient cannabis from Central Asia","volume":"59","author":"Russo","year":"2008","journal-title":"J. Exp. Bot."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cbdv.200790144","article-title":"History of cannabis and its preparations in saga, science, and sobriquet","volume":"4","author":"Russo","year":"2007","journal-title":"Chem. Biodivers."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.mehy.2005.08.026","article-title":"A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol","volume":"66","author":"Russo","year":"2006","journal-title":"Med. Hypotheses"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1021\/ja01092a065","article-title":"Total Synthesis of Dl-\u03b4-1-Tetrahydrocannabinol, the Active Constituent of Hashish","volume":"87","author":"Mechoulam","year":"1965","journal-title":"J. Am. Chem. Soc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2005.03.002","article-title":"Cannabinoids and neuroprotection in CNS inflammatory disease","volume":"233","author":"Jackson","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/09540260902782828","article-title":"The endocannabinoid system in neuropathological states","volume":"21","author":"Orgado","year":"2009","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_11","first-page":"1","article-title":"Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis","volume":"5","author":"Slatkin","year":"2007","journal-title":"J. Support. Oncol."},{"key":"ref_12","unstructured":"Lutge, E.E., Gray, A., and Siegfried, N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV\/AIDS. Available online:http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD005175.pub3\/pdf\/standard."},{"key":"ref_13","first-page":"531","article-title":"Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain","volume":"4","author":"Sutton","year":"2006","journal-title":"J. Support Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","article-title":"Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study","volume":"10","author":"Vaney","year":"2004","journal-title":"Mult. Scler."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1211\/0022357022304","article-title":"Medicinal cannabis: Is \u03949-tetrahydrocannabinol necessary for all its effects?","volume":"55","author":"Wilkinson","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"ElSohly, M.A. (2007). Marijuana and the Cannabinoids, Humana Press.","DOI":"10.1007\/978-1-59259-947-9"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.phytochem.2012.11.001","article-title":"Analysis of cannabinoids in laser-microdissected trichomes of medicinal Cannabis sativa using LCMS and cryogenic NMR","volume":"87","author":"Happyana","year":"2013","journal-title":"Phytochemistry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1126\/science.175.4023.778","article-title":"Cannabinoids with a propyl side chain in cannabis: Occurrence and chromatographic behavior","volume":"175","author":"Wijsbeek","year":"1972","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/genetics\/163.1.335","article-title":"The inheritance of chemical phenotype in Cannabis sativa L","volume":"163","author":"Bagatta","year":"2003","journal-title":"Genetics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10681-004-4759-6","article-title":"Potential of marker assisted selection in hemp genetic improvement","volume":"140","author":"Mandolino","year":"2004","journal-title":"Euphytica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1300\/J237v09n01_04","article-title":"Accumulation of cannabinoids in glandular trichomes of Cannabis (Cannabaceae)","volume":"9","author":"Mahlberg","year":"2004","journal-title":"J. Ind. Hemp."},{"key":"ref_22","unstructured":"Basile, A. (2014). Understanding the Regulating Mechanisms behind Cannabinoid Biosynthesis. [Ph.D. Thesis, Scuola Superiore Sant\u2019Anna]."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0031-9422(98)00278-7","article-title":"Purification and characterization of cannabichromenic acid synthase from Cannabis sativa","volume":"49","author":"Morimoto","year":"1998","journal-title":"Phytochemistry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jmb.2012.06.030","article-title":"Structure and function of 1-tetrahydrocannabinolic acid (THCA) synthase, the enzyme controlling the psychoactivity of Cannabis sativa","volume":"423","author":"Shoyama","year":"2012","journal-title":"J. Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1074\/jbc.270.8.3726","article-title":"An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing","volume":"270","author":"Shire","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.febslet.2004.11.085","article-title":"Identification and characterisation of a novel splice variant of the human CB1 receptor","volume":"579","author":"Ryberg","year":"2005","journal-title":"FEBS Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1006\/nimg.2001.0939","article-title":"Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain","volume":"14","author":"Biegon","year":"2001","journal-title":"NeuroImage"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0306-4522(96)00428-9","article-title":"Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain","volume":"77","author":"Glass","year":"1997","journal-title":"Neuroscience"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Duncan","year":"2005","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1471-4159.2005.03380.x","article-title":"Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli","volume":"95","author":"Maresz","year":"2005","journal-title":"J. Neurochem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neulet.2006.10.053","article-title":"Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain","volume":"412","author":"Ashton","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1054\/plef.2001.0341","article-title":"Cannabinoid receptors and their ligands","volume":"66","author":"Pertwee","year":"2002","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0083-6729(02)65066-6","article-title":"Endocannabinoids and their actions","volume":"65","author":"Maccarrone","year":"2002","journal-title":"Vitam. Horm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0026-895X(25)13215-X","article-title":"Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells","volume":"44","author":"Mackie","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjp.0707527","article-title":"The peripheral cannabinoid receptor knockout mice: An update","volume":"153","author":"Buckley","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Valverde, O., Karsak, M., and Zimmer, A. (2005). Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Handb. Exp. Pharmacol., 117\u2013145.","DOI":"10.1007\/3-540-26573-2_4"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/35082088","article-title":"Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition","volume":"411","author":"Chuang","year":"2001","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1126\/science.288.5464.306","article-title":"Impaired nociception and pain sensation in mice lacking the capsaicin receptor","volume":"288","author":"Caterina","year":"2000","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.neuroscience.2006.02.074","article-title":"Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain","volume":"139","author":"Cristino","year":"2006","journal-title":"Neuroscience"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1073\/pnas.97.7.3655","article-title":"Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human","volume":"97","author":"Mezey","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bjp.0707481","article-title":"Novel cannabinoid receptors","volume":"152","author":"Brown","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2)","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2005.11.003","article-title":"In silico patent searching reveals a new cannabinoid receptor","volume":"27","author":"Baker","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1476-5381.2009.00625.x","article-title":"GPR55 ligands promote receptor coupling to multiple signalling pathways","volume":"160","author":"Henstridge","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jb\/mvp208","article-title":"Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells","volume":"147","author":"Oka","year":"2010","journal-title":"J. Biochem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"24631","DOI":"10.1074\/jbc.270.42.24631","article-title":"G alpha 12 and G alpha 13 stimulate Rho-dependent stress fiber formation and focal adhesion assembly","volume":"270","author":"Buhl","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"McHugh, D., Hu, S.S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J.M., and Bradshaw, H.B. (2010). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci., 11.","DOI":"10.1186\/1471-2202-11-44"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1006\/geno.1997.4752","article-title":"Cloning and chromosomal localization of a gene (GPR18) encoding a novel seven transmembrane receptor highly expressed in spleen and testis","volume":"42","author":"Gantz","year":"1997","journal-title":"Genomics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0014-5793(03)01196-7","article-title":"Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives","volume":"554","author":"Fredriksson","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2006.02.004","article-title":"Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents","volume":"3","author":"Overton","year":"2006","journal-title":"Cell Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0014-2999(86)90782-X","article-title":"(\u2212)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists","volume":"128","author":"Sprouse","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0306-4522(91)90128-B","article-title":"5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex","volume":"40","author":"Araneda","year":"1991","journal-title":"Neuroscience"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans R. Soc. Lond. B Biol. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2008.10.001","article-title":"Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?","volume":"30","author":"Kunos","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.imbio.2009.12.006","article-title":"Interaction between cytokines, cannabinoids and the nervous system","volume":"215","author":"Gran","year":"2010","journal-title":"Immunobiology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2006.01.047","article-title":"Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-\u03baB involvement","volume":"399","author":"Esposito","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"H610","DOI":"10.1152\/ajpheart.00236.2007","article-title":"Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption","volume":"293","author":"Rajesh","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/bph.12492","article-title":"The influence of cannabinoids on generic traits of neurodegeneration","volume":"171","author":"Fagan","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2004.6.3\/galexander","article-title":"Biology of Parkinson\u2019s disease: Pathogenesis and pathophysiology of a multisystem neurodegenerative disorder","volume":"6","author":"Alexander","year":"2004","journal-title":"Dialog. Clin. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/187152712800792785","article-title":"A synopsis on the role of tyrosine hydroxylase in Parkinson\u2019s disease","volume":"11","author":"Tabrez","year":"2012","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2174\/0929867013372995","article-title":"Parkinson\u2019s disease\u2014Redox mechanisms","volume":"8","author":"Adams","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1471-4892(02)00011-5","article-title":"CB1 cannabinoid receptor signalling in Parkinson\u2019s disease","volume":"3","author":"Brotchie","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","article-title":"Experimental parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission","volume":"22","author":"Gubellini","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/ana.20462","article-title":"High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson\u2019s disease patients","volume":"57","author":"Pisani","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/mds.23014","article-title":"Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson\u2019s disease patients","volume":"25","author":"Pisani","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00702-003-0033-7","article-title":"Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain","volume":"110","author":"Hurley","year":"2003","journal-title":"J. Neural. Transm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/mds.23457","article-title":"Homeostatic changes of the endocannabinoid system in Parkinson\u2019s disease","volume":"26","author":"Pisani","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Buchanan, R.J., Darrow, D.P., Meier, K.T., Robinson, J., Schiehser, D.M., Glahn, D.C., and Nadasdy, Z. (2014). Changes in GABA and glutamate concentrations during memory tasks in patients with Parkinson\u2019s disease undergoing DBS surgery. Front. Hum. Neurosci., 8.","DOI":"10.3389\/fnhum.2014.00081"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157015909788848893","article-title":"Towards a reconceptualization of striatal interactions between glutamatergic and dopaminergic neurotransmission and their contribution to the production of movements","volume":"7","author":"David","year":"2009","journal-title":"Curr. Neuropharm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/187152709789824606","article-title":"Glutamate receptors as therapeutic targets for Parkinson\u2019s disease","volume":"8","author":"Johnson","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.1016\/S1353-8020(08)70025-7","article-title":"Excitotoxicity and new antiglutamatergic strategies in Parkinson\u2019s disease and Alzheimer\u2019s disease","volume":"13","author":"Koutsilieri","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00002512-200016040-00003","article-title":"Tremor-predominant Parkinson\u2019s disease. Approaches to treatment","volume":"16","author":"Koller","year":"2000","journal-title":"Drugs Aging"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1006\/exnr.1997.6645","article-title":"The cannabinoid receptor agonist WIN 55,212\u20132 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson\u2019s disease","volume":"148","author":"Maneuf","year":"1997","journal-title":"Exp. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson\u2019s disease","volume":"19","author":"Ramos","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1476-5381.2011.01365.x","article-title":"Prospects for cannabinoid therapies in basal ganglia disorders","volume":"163","author":"Valdeolivas","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2174\/187152709789824642","article-title":"Cannabinoids and Parkinson\u2019s disease","volume":"8","author":"Garcia","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","article-title":"Symptom-relieving and neuroprotective effects of the phytocannabinoid \u03949-THCV in animal models of Parkinson\u2019s disease","volume":"163","author":"Garcia","year":"2011","journal-title":"Br. J. Pharmacol"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1006\/nbdi.1998.0220","article-title":"Brain cannabinoid systems as targets for the therapy of neurological disorders","volume":"5","author":"Consroe","year":"1998","journal-title":"Neurobiol Dis."},{"key":"ref_86","first-page":"23","article-title":"Cannabis in movement disorders","volume":"6","author":"Kolbe","year":"1999","journal-title":"Forsch Komplement."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/mds.870130603","article-title":"Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson\u2019s disease","volume":"13","author":"Brotchie","year":"1998","journal-title":"Mov. Disord."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0091-3057(00)00390-7","article-title":"Cannabinoid and dopamine interaction in rodent brain: Effects on locomotor activity","volume":"67","author":"Meschler","year":"2000","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: A pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","article-title":"Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study","volume":"63","author":"Carroll","year":"2004","journal-title":"Neurology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Francelle, L., Galvan, L., and Brouillet, E. (2014). Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington\u2019s disease. Front. Cell Neurosci., 8.","DOI":"10.3389\/fncel.2014.00295"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1734-1140(10)70238-3","article-title":"Huntington\u2019s disease: Pathogenesis to animal models","volume":"62","author":"Kumar","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/jnnp.58.2.192","article-title":"Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington\u2019s disease","volume":"58","author":"Swerdlow","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/157488912798842278","article-title":"Cannabinoids: Novel medicines for the treatment of Huntington\u2019s disease","volume":"7","author":"Sagredo","year":"2012","journal-title":"Recent Pat. CNS Drug. Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: From molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_98","first-page":"9","article-title":"A theory of the functional organization of the neostriatum and the neostriatal control of voluntary movement","volume":"286","author":"Groves","year":"1983","journal-title":"Brain Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev.ne.06.030183.000445","article-title":"Speculations on the functional anatomy of basal ganglia disorders","volume":"6","author":"Penney","year":"1983","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington\u2019s disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8257","DOI":"10.1073\/pnas.1400988111","article-title":"A restricted population of CB1 cannabinoid receptors with neuroprotective activity","volume":"111","author":"Chiarlone","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M.L., Munoz, E., and Sagredo, O. (2014). Neuroprotective Properties of Cannabigerol in Huntington\u2019s Disease: Studies in R6\/2 Mice and 3-Nitropropionate-lesioned Mice. Neurotherapeutics, 1\u201314.","DOI":"10.1007\/s13311-014-0304-z"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/cn200114w","article-title":"Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington\u2019s disease: Role of CB1 and CB2 receptors","volume":"3","author":"Valdeolivas","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jnr.22682","article-title":"Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington\u2019s disease","volume":"89","author":"Sagredo","year":"2011","journal-title":"J. Neurosci. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tips.2006.11.001","article-title":"Cannabinoid CB2 receptor: A new target for controlling neural cell survival?","volume":"28","author":"Romero","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1476-5381.2010.00773.x","article-title":"Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington\u2019s disease","volume":"160","author":"Scotter","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington\u2019s disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/jnp.2006.18.4.553","article-title":"Nabilone could treat chorea and irritability in Huntington\u2019s disease","volume":"18","author":"Curtis","year":"2006","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO;2-7","article-title":"Nabilone increases choreatic movements in Huntington\u2019s disease","volume":"14","author":"Schneider","year":"1999","journal-title":"Mov. Disord."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1474-4422(11)70072-2","article-title":"The projected effect of risk factor reduction on Alzheimer\u2019s disease prevalence","volume":"10","author":"Barnes","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A beta oligomers\u2014A decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/156720506779025279","article-title":"The role of tau phosphorylation in the pathogenesis of Alzheimer\u2019s disease","volume":"3","author":"Mi","year":"2006","journal-title":"Curr. Alzheimer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjp.0707505","article-title":"Cannabinoid CB2 receptors in human brain inflammation","volume":"153","author":"Benito","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1021\/mp060066m","article-title":"A molecular link between the active component of marijuana and Alzheimer\u2019s disease pathology","volume":"3","author":"Eubanks","year":"2006","journal-title":"Mol. Pharm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1471-4159.2003.02327.x","article-title":"Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells","volume":"89","author":"Iuvone","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.bjp.0707337","article-title":"Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1\u03b2 and iNOS expression","volume":"151","author":"Esposito","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer\u2019s disease","volume":"79","author":"Reigada","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ptr.5095","article-title":"Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARgamma involvement","volume":"28","author":"Scuderi","year":"2014","journal-title":"Phytother. Res."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Aso, E., Sanchez-Pla, A., Vegas-Lozano, E., Maldonado, R., and Ferrer, I. Cannabis-Based Medicine Reduces Multiple Pathological Processes in AbetaPP\/PS1 Mice. Available online: http:\/\/scibite.com\/site\/library\/2014_8\/1\/0\/25125475.html.","DOI":"10.3233\/JAD-141014"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","article-title":"\u03949-tetrahydrocannabinol for nighttime agitation in severe dementia","volume":"185","author":"Walther","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(07)96001-0","article-title":"New insights into adaptive immunity in chronic neuroinflammation","volume":"96","author":"Siffrin","year":"2007","journal-title":"Adv. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.bjp.0707003","article-title":"Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors","volume":"150","author":"Pryce","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0165-5728(89)90075-1","article-title":"Delta 9-tetrahydrocannabinol: A novel treatment for experimental autoimmune encephalomyelitis","volume":"23","author":"Lyman","year":"1989","journal-title":"J. Neuroimmunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1523\/JNEUROSCI.22-22-09742.2002","article-title":"Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase\/Akt signaling","volume":"22","author":"Vela","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/0-306-47611-8_24","article-title":"Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: Evidence for CB1 receptor participation","volume":"493","author":"Cabral","year":"2001","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_129","first-page":"1","article-title":"The cannabinoid system and cytokine network","volume":"225","author":"Klein","year":"2000","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1523\/JNEUROSCI.23-07-02511.2003","article-title":"Therapeutic action of cannabinoids in a murine model of multiple sclerosis","volume":"23","author":"Vela","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.neuroscience.2013.09.005","article-title":"Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis","volume":"254","author":"Ribeiro","year":"2013","journal-title":"Neuroscience"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.nbd.2005.03.002","article-title":"Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and\/or vanilloid receptors in a rat model of multiple sclerosis","volume":"20","author":"Cabranes","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.brainres.2006.06.001","article-title":"Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice","volume":"1107","author":"Cabranes","year":"2006","journal-title":"Brain Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/35003583","article-title":"Cannabinoids control spasticity and tremor in a multiple sclerosis model","volume":"404","author":"Baker","year":"2000","journal-title":"Nature"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jep.2010.11.035","article-title":"Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis","volume":"133","author":"Buccellato","year":"2011","journal-title":"J. Ethnopharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1517\/13543784.15.4.351","article-title":"Targeting the endocannabinoid system in treating brain disorders","volume":"15","author":"Bahr","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1093\/brain\/awm160","article-title":"The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis","volume":"130","author":"Centonze","year":"2007","journal-title":"Brain"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jns.2009.07.021","article-title":"Plasma endocannabinoid levels in multiple sclerosis","volume":"287","author":"Feng","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1748-1716.2006.01652.x","article-title":"The spinal pathophysiology of spasticity\u2014From a basic science point of view","volume":"189","author":"Nielsen","year":"2007","journal-title":"Acta Physiol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1191\/1352458502ms795rr","article-title":"Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: A systematic review","volume":"8","author":"Paisley","year":"2002","journal-title":"Mult. Scler."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial","volume":"362","author":"Zajicek","year":"2003","journal-title":"Lancet"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/jnnp.2005.070136","article-title":"Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up","volume":"76","author":"Zajicek","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S1474-4422(13)70159-5","article-title":"Cupid investigator group. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): A randomised, placebo-controlled trial","volume":"12","author":"Zajicek","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Turcotte, D., Doupe, M., Torabi, M., Gomori, A., Ethans, K., Esfahani, F., Galloway, K., and Namaka, M. (2014). Nabilone as an Adjunctive to Gabapentin for Multiple Sclerosis-Induced Neuropathic Pain: A Randomized Controlled Trial. Pain Med.","DOI":"10.1111\/pme.12569"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00192-006-0086-x","article-title":"The effect of cannabis on urge incontinence in patients with multiple sclerosis: A multicentre, randomised placebo-controlled trial (CAMS-LUTS)","volume":"17","author":"Freeman","year":"2006","journal-title":"Int. Urogynecol. J. Pelvic Floor Dysfunct."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s003350010205","article-title":"Mice, the motor system, and human motor neuron pathology","volume":"11","author":"Nicholson","year":"2000","journal-title":"Mamm. Genome"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"I7","DOI":"10.1007\/s004150050552","article-title":"The role of excitotoxicity in ALS\u2014What is the evidence?","volume":"247","author":"Ludolph","year":"2000","journal-title":"J. Neurol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"I1","DOI":"10.1007\/s004150050551","article-title":"Oxidative stress in amyotrophic lateral sclerosis","volume":"247","author":"Robberecht","year":"2000","journal-title":"J. Neurol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14660820310016813","article-title":"Amyotrophic lateral sclerosis: Delayed disease progression in mice by treatment with a cannabinoid","volume":"5","author":"Raman","year":"2004","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron. Disord."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1096\/fj.05-4743fje","article-title":"Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice","volume":"20","author":"Bilsland","year":"2006","journal-title":"FASEB J."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/14660820510030149","article-title":"Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival","volume":"6","author":"Weydt","year":"2005","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron. Disord."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer\u2019s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ramirez","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejphar.2006.05.025","article-title":"AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis","volume":"542","author":"Kim","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/cns.12262","article-title":"Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex((R)) -like combination of phytocannabinoids: Interest for future therapies in amyotrophic lateral sclerosis","volume":"20","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Yiangou, Y., Facer, P., Durrenberger, P., Chessell, I.P., Naylor, A., Bountra, C., Banati, R.R., and Anand, P. (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol., 6.","DOI":"10.1186\/1471-2377-6-12"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/104990910101800411","article-title":"Marijuana in the management of amyotrophic lateral sclerosis","volume":"18","author":"Carter","year":"2001","journal-title":"Am. J. Hosp. Palliat. Care"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/104990910402100206","article-title":"Survey of cannabis use in patients with amyotrophic lateral sclerosis","volume":"21","author":"Amtmann","year":"2004","journal-title":"Am. J. Hosp. Palliat. Care"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.clineuro.2009.04.001","article-title":"The complexity of neurobiological processes in acute ischemic stroke","volume":"111","author":"Brouns","year":"2009","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s13311-011-0040-6","article-title":"Investigational therapies for ischemic stroke: Neuroprotection and neurorecovery","volume":"8","author":"Sahota","year":"2011","journal-title":"Neurotherapeutics"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1189\/jlb.1109766","article-title":"Inflammatory mechanisms in ischemic stroke: Role of inflammatory cells","volume":"87","author":"Jin","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2174\/13816128113199990434","article-title":"Therapeutic potential of cannabinoids in neurodegenerative disorders: A selective review","volume":"20","author":"Velayudhan","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1203\/PDR.0b013e318186e5dd","article-title":"Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets","volume":"64","author":"Alvarez","year":"2008","journal-title":"Pediatr. Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/01.STR.0000163083.59201.34","article-title":"Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism","volume":"36","author":"Mishima","year":"2005","journal-title":"Stroke"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(05)70253-2","article-title":"Efficacy and safety of dexanabinol in severe traumatic brain injury: Results of a phase III randomised, placebo-controlled, clinical trial","volume":"5","author":"Maas","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1056\/NEJMra041996","article-title":"Neonatal brain injury","volume":"351","author":"Ferriero","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.neuropharm.2012.05.034","article-title":"Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function","volume":"63","author":"Pazos","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.nbd.2009.10.023","article-title":"The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors","volume":"37","author":"Castillo","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","article-title":"Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT(1A) and CB2 receptors","volume":"71","author":"Pazos","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMra022308","article-title":"Epilepsy","volume":"349","author":"Chang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14728214.12.3.407","article-title":"Emerging drugs for epilepsy","volume":"12","author":"Kwan","year":"2007","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0022-3565(25)12911-X","article-title":"In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): Inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity","volume":"277","author":"Compton","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1528-1167.2010.02523.x","article-title":"\u03949-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats","volume":"51","author":"Hill","year":"2010","journal-title":"Epilepsia"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/j.1476-5381.2012.02207.x","article-title":"Cannabidivarin is anticonvulsant in mouse and rat","volume":"167","author":"Hill","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1523\/JNEUROSCI.4212-08.2009","article-title":"Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels","volume":"29","author":"Ryan","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00223-006-0171-7","article-title":"Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors","volume":"80","author":"Scutt","year":"2007","journal-title":"Calcif. Tissue Int."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"Ligresti","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1083\/jcb.200305129","article-title":"Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain","volume":"163","author":"Bisogno","year":"2003","journal-title":"J. Cell. Biol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2174\/092986710790980050","article-title":"Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists","volume":"17","author":"Pertwee","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/bjp.2008.190","article-title":"Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes","volume":"154","author":"Dennis","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/bjp.2008.57","article-title":"The phytocannabinoid \u03949-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum","volume":"154","author":"Ma","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","article-title":"Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats","volume":"199","author":"Campos","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/cbdv.200790150","article-title":"Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine","volume":"4","author":"Russo","year":"2007","journal-title":"Chem. Biodivers."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.nurt.2009.08.002","article-title":"Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside","volume":"6","author":"Rahn","year":"2009","journal-title":"Neurotherapeutics"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/brain\/awr271","article-title":"Neurological diseases and pain","volume":"135","author":"Borsook","year":"2012","journal-title":"Brain"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00019052-200110000-00014","article-title":"Neuropathic pain","volume":"14","author":"Koltzenburg","year":"2001","journal-title":"Curr. Opin. Neurol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.3390\/molecules19032877","article-title":"Use of natural compounds in the management of diabetic peripheral neuropathy","volume":"19","author":"Galuppo","year":"2014","journal-title":"Molecules"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2006.11.006","article-title":"The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain","volume":"556","author":"Costa","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/28393","article-title":"Control of pain initiation by endogenous cannabinoids","volume":"394","author":"Calignano","year":"1998","journal-title":"Nature"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1006\/mcne.2000.0844","article-title":"Cannabinoid CB(1) receptor expression in rat spinal cord","volume":"15","author":"Egertova","year":"2000","journal-title":"Mol. Cell. Neurosci."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/19\/11\/18781\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:09:29Z","timestamp":1760216969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/19\/11\/18781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,17]]},"references-count":190,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11]]}},"alternative-id":["molecules191118781"],"URL":"https:\/\/doi.org\/10.3390\/molecules191118781","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,17]]}}}